Amylyx Pharmaceuticals’ avexitide led to statistically significant and clinically meaningful reductions in hypoglycemic events in patients with post-bariatric hypoglycemia (PBH). This peptide drug, a GLP-1 antagonist, was acquired from Eiger BioPharmaceuticals in 2024.
Unlike GLP-1 agonist drugs marketed for weight loss, new Amylyx Pharmaceuticals drug avexitide blocks its target receptor. Amylyx plans to advance this GLP-1 antagonist into Phase 3 testing for post-bariatric hypoglycemia, a rare condition in which blood sugar levels drop precipitously.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.